Inhibition of WEE1 Is Effective in TP53 - and RAS -Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring

Outcomes in -mutant metastatic colorectal cancer (mCRC) remain poor and patients have limited therapeutic options. Adavosertib is the first small-molecule inhibitor of WEE1 kinase. We hypothesized that aberrations in DNA replication seen in mCRC with both and mutations would sensitize tumors to WEE1...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical oncology 2021-11, Vol.39 (33), p.3705-3715
Hauptverfasser:	Seligmann, Jenny F, Fisher, David J, Brown, Louise C, Adams, Richard A, Graham, Janet, Quirke, Philip, Richman, Susan D, Butler, Rachel, Domingo, Enric, Blake, Andrew, Yates, Emma, Braun, Michael, Collinson, Fiona, Jones, Rob, Brown, Ewan, de Winton, Emma, Humphrey, Timothy C, Parmar, Mahesh, Kaplan, Richard, Wilson, Richard H, Seymour, Matthew, Maughan, Timothy S
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cell Cycle Proteins - antagonists & inhibitors Colorectal Neoplasms - drug therapy Colorectal Neoplasms - genetics Colorectal Neoplasms - metabolism Colorectal Neoplasms - pathology Enzyme Inhibitors - therapeutic use Female Follow-Up Studies Humans Male Middle Aged Mutation Neoplasm Metastasis ORIGINAL REPORTS Prognosis Protein-Tyrosine Kinases - antagonists & inhibitors Pyrazoles - therapeutic use Pyrimidinones - therapeutic use Quality of Life ras Proteins - genetics Survival Rate Tumor Suppressor Protein p53 - genetics Watchful Waiting - statistics & numerical data
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!